In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood

M. A. Pfaller, D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, R. N. Jones, L. Steele-Moore, Gerald Denys, C. Staley, J. R. Dispersio, M. Saubolle, M. L. Wilson, G. D. Overturf, L. R. Peterson, P. C. Schreckenberger, G. V. Doern

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

We determined the in vitro susceptibilities of 314 strains of Candida spp., representing 13 species rarely isolated from blood, to posaconazole and voriconazole as well as four licensed systemic antifungal agents (amphotericin B, flucytosine, fluconazole, and itraconazole). The organisms included 153 isolates of C. krusei, 67 isolates of C. lusitaniae, 48 isolates of C. guilliermondii, 10 isolates of C. famata, 10 isolates of C. kefyr, 6 isolates of C. pelliculosa, 5 isolates of C. rugosa, 4 isolates of C. lipolytica, 3 isolates of C. dubliniensis, 3 isolates of C. inconspicua, 2 isolates of C. sake, and 1 isolate each of C. lambica, C. norvegensis, and C. zeylanoides. MIC determinations were made by the National Committee for Clinical Laboratory Standards reference broth microdilution method and Etest (amphotericin B). Resistance to both amphotericin B and fluconazole was observed in strains of C. krusei, C. lusitaniae, C. guilliermondii, C. inconspicua, and C. sake. Resistance to amphotericin B, but not to fluconazole, was also observed among isolates of C. kefyr and C. rugosa. Posaconazole and voriconazole were active (MIC, ≤1 μg/ml) against 94 to 100% of these isolates. In contrast to the more common species of Candida causing bloodstream infection, these rare species appear to be less susceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole. Continued surveillance will be necessary to detect the emergence of these species as more prevalent, resistant pathogens. The new triazoles appear to offer acceptable coverage of uncommon Candida sp. bloodstream infections.

Original languageEnglish (US)
Pages (from-to)78-83
Number of pages6
JournalJournal of clinical microbiology
Volume41
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Antifungal Agents
Amphotericin B
Candida
Fluconazole
Disk Diffusion Antimicrobial Tests
Flucytosine
Triazoles
Itraconazole
Infection
Voriconazole
posaconazole
In Vitro Techniques

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. / Pfaller, M. A.; Diekema, D. J.; Messer, S. A.; Boyken, L.; Hollis, R. J.; Jones, R. N.; Steele-Moore, L.; Denys, Gerald; Staley, C.; Dispersio, J. R.; Saubolle, M.; Wilson, M. L.; Overturf, G. D.; Peterson, L. R.; Schreckenberger, P. C.; Doern, G. V.

In: Journal of clinical microbiology, Vol. 41, No. 1, 01.01.2003, p. 78-83.

Research output: Contribution to journalArticle

Pfaller, MA, Diekema, DJ, Messer, SA, Boyken, L, Hollis, RJ, Jones, RN, Steele-Moore, L, Denys, G, Staley, C, Dispersio, JR, Saubolle, M, Wilson, ML, Overturf, GD, Peterson, LR, Schreckenberger, PC & Doern, GV 2003, 'In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood', Journal of clinical microbiology, vol. 41, no. 1, pp. 78-83. https://doi.org/10.1128/JCM.41.1.78-83.2003
Pfaller, M. A. ; Diekema, D. J. ; Messer, S. A. ; Boyken, L. ; Hollis, R. J. ; Jones, R. N. ; Steele-Moore, L. ; Denys, Gerald ; Staley, C. ; Dispersio, J. R. ; Saubolle, M. ; Wilson, M. L. ; Overturf, G. D. ; Peterson, L. R. ; Schreckenberger, P. C. ; Doern, G. V. / In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. In: Journal of clinical microbiology. 2003 ; Vol. 41, No. 1. pp. 78-83.
@article{59c738e561174c90985cffdb2e7c6f76,
title = "In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood",
abstract = "We determined the in vitro susceptibilities of 314 strains of Candida spp., representing 13 species rarely isolated from blood, to posaconazole and voriconazole as well as four licensed systemic antifungal agents (amphotericin B, flucytosine, fluconazole, and itraconazole). The organisms included 153 isolates of C. krusei, 67 isolates of C. lusitaniae, 48 isolates of C. guilliermondii, 10 isolates of C. famata, 10 isolates of C. kefyr, 6 isolates of C. pelliculosa, 5 isolates of C. rugosa, 4 isolates of C. lipolytica, 3 isolates of C. dubliniensis, 3 isolates of C. inconspicua, 2 isolates of C. sake, and 1 isolate each of C. lambica, C. norvegensis, and C. zeylanoides. MIC determinations were made by the National Committee for Clinical Laboratory Standards reference broth microdilution method and Etest (amphotericin B). Resistance to both amphotericin B and fluconazole was observed in strains of C. krusei, C. lusitaniae, C. guilliermondii, C. inconspicua, and C. sake. Resistance to amphotericin B, but not to fluconazole, was also observed among isolates of C. kefyr and C. rugosa. Posaconazole and voriconazole were active (MIC, ≤1 μg/ml) against 94 to 100{\%} of these isolates. In contrast to the more common species of Candida causing bloodstream infection, these rare species appear to be less susceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole. Continued surveillance will be necessary to detect the emergence of these species as more prevalent, resistant pathogens. The new triazoles appear to offer acceptable coverage of uncommon Candida sp. bloodstream infections.",
author = "Pfaller, {M. A.} and Diekema, {D. J.} and Messer, {S. A.} and L. Boyken and Hollis, {R. J.} and Jones, {R. N.} and L. Steele-Moore and Gerald Denys and C. Staley and Dispersio, {J. R.} and M. Saubolle and Wilson, {M. L.} and Overturf, {G. D.} and Peterson, {L. R.} and Schreckenberger, {P. C.} and Doern, {G. V.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1128/JCM.41.1.78-83.2003",
language = "English (US)",
volume = "41",
pages = "78--83",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood

AU - Pfaller, M. A.

AU - Diekema, D. J.

AU - Messer, S. A.

AU - Boyken, L.

AU - Hollis, R. J.

AU - Jones, R. N.

AU - Steele-Moore, L.

AU - Denys, Gerald

AU - Staley, C.

AU - Dispersio, J. R.

AU - Saubolle, M.

AU - Wilson, M. L.

AU - Overturf, G. D.

AU - Peterson, L. R.

AU - Schreckenberger, P. C.

AU - Doern, G. V.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - We determined the in vitro susceptibilities of 314 strains of Candida spp., representing 13 species rarely isolated from blood, to posaconazole and voriconazole as well as four licensed systemic antifungal agents (amphotericin B, flucytosine, fluconazole, and itraconazole). The organisms included 153 isolates of C. krusei, 67 isolates of C. lusitaniae, 48 isolates of C. guilliermondii, 10 isolates of C. famata, 10 isolates of C. kefyr, 6 isolates of C. pelliculosa, 5 isolates of C. rugosa, 4 isolates of C. lipolytica, 3 isolates of C. dubliniensis, 3 isolates of C. inconspicua, 2 isolates of C. sake, and 1 isolate each of C. lambica, C. norvegensis, and C. zeylanoides. MIC determinations were made by the National Committee for Clinical Laboratory Standards reference broth microdilution method and Etest (amphotericin B). Resistance to both amphotericin B and fluconazole was observed in strains of C. krusei, C. lusitaniae, C. guilliermondii, C. inconspicua, and C. sake. Resistance to amphotericin B, but not to fluconazole, was also observed among isolates of C. kefyr and C. rugosa. Posaconazole and voriconazole were active (MIC, ≤1 μg/ml) against 94 to 100% of these isolates. In contrast to the more common species of Candida causing bloodstream infection, these rare species appear to be less susceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole. Continued surveillance will be necessary to detect the emergence of these species as more prevalent, resistant pathogens. The new triazoles appear to offer acceptable coverage of uncommon Candida sp. bloodstream infections.

AB - We determined the in vitro susceptibilities of 314 strains of Candida spp., representing 13 species rarely isolated from blood, to posaconazole and voriconazole as well as four licensed systemic antifungal agents (amphotericin B, flucytosine, fluconazole, and itraconazole). The organisms included 153 isolates of C. krusei, 67 isolates of C. lusitaniae, 48 isolates of C. guilliermondii, 10 isolates of C. famata, 10 isolates of C. kefyr, 6 isolates of C. pelliculosa, 5 isolates of C. rugosa, 4 isolates of C. lipolytica, 3 isolates of C. dubliniensis, 3 isolates of C. inconspicua, 2 isolates of C. sake, and 1 isolate each of C. lambica, C. norvegensis, and C. zeylanoides. MIC determinations were made by the National Committee for Clinical Laboratory Standards reference broth microdilution method and Etest (amphotericin B). Resistance to both amphotericin B and fluconazole was observed in strains of C. krusei, C. lusitaniae, C. guilliermondii, C. inconspicua, and C. sake. Resistance to amphotericin B, but not to fluconazole, was also observed among isolates of C. kefyr and C. rugosa. Posaconazole and voriconazole were active (MIC, ≤1 μg/ml) against 94 to 100% of these isolates. In contrast to the more common species of Candida causing bloodstream infection, these rare species appear to be less susceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole. Continued surveillance will be necessary to detect the emergence of these species as more prevalent, resistant pathogens. The new triazoles appear to offer acceptable coverage of uncommon Candida sp. bloodstream infections.

UR - http://www.scopus.com/inward/record.url?scp=12244253033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244253033&partnerID=8YFLogxK

U2 - 10.1128/JCM.41.1.78-83.2003

DO - 10.1128/JCM.41.1.78-83.2003

M3 - Article

VL - 41

SP - 78

EP - 83

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 1

ER -